# Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

> **NCT02526511** · NA · UNKNOWN · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 75 (actual)

## Conditions studied

- Stage I Renal Cell Cancer
- Stage II Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **PROCEDURE:** Arterial Spin Labeling Magnetic Resonance Imaging
- **PROCEDURE:** Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- **PROCEDURE:** Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- **PROCEDURE:** Perfusion Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT02526511
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04-15
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-09-07
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-04-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02526511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02526511, "Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02526511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*